OP Asset Management Ltd acquired a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) in the 1st quarter, HoldingsChannel reports. The firm acquired 3,718 shares of the company’s stock, valued at approximately $1,785,000.
Other institutional investors also recently modified their holdings of the company. Optiver Holding B.V. acquired a new position in shares of Medpace in the 3rd quarter worth approximately $27,000. Geneos Wealth Management Inc. increased its holdings in Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after purchasing an additional 37 shares in the last quarter. Steigerwald Gordon & Koch Inc. acquired a new stake in Medpace during the 4th quarter valued at $30,000. Elyxium Wealth LLC bought a new position in Medpace in the 4th quarter valued at $30,000. Finally, Quarry LP bought a new position in Medpace in the 3rd quarter valued at $35,000. Institutional investors own 77.98% of the company’s stock.
Insider Buying and Selling at Medpace
In related news, General Counsel Stephen P. Ewald sold 16,349 shares of the business’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the completion of the sale, the general counsel directly owned 20,343 shares of the company’s stock, valued at $9,154,350. The trade was a 44.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 20.50% of the stock is currently owned by company insiders.
Analyst Upgrades and Downgrades
Check Out Our Latest Stock Analysis on Medpace
Medpace Price Performance
Medpace stock opened at $527.07 on Monday. The business’s 50-day simple moving average is $451.19 and its 200 day simple moving average is $496.65. The stock has a market cap of $15.05 billion, a price-to-earnings ratio of 33.13, a P/E/G ratio of 2.67 and a beta of 1.18. Medpace Holdings, Inc. has a 12-month low of $306.70 and a 12-month high of $628.92.
Medpace (NASDAQ:MEDP – Get Free Report) last announced its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, topping the consensus estimate of $3.74 by $0.54. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The firm had revenue of $706.60 million during the quarter, compared to analysts’ expectations of $697.82 million. During the same period in the previous year, the business posted $3.67 EPS. The company’s quarterly revenue was up 26.5% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, sell-side analysts expect that Medpace Holdings, Inc. will post 17.04 EPS for the current year.
Medpace Profile
Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.
Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.
Read More
- Five stocks we like better than Medpace
- As Stablecoins Keep Growing, These 2 Stocks Benefit
- Apple Just Handed These 4 Memory Stocks Their Best News of the Year
- Costco’s Secret Growth Engine May Be Running Out of Gas
- Why Alphabet’s Pullback May Be an Opportunity in Disguise
Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report).
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.
